Abstract
An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 μg TNF and 40 μg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24–26°C, anti-tumour effects were lost, whereas temperatures of 38–39°C or 42–43°C resulted in higher response rates. However, at 42–43°C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 μg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38°C was mandatory. Moreover, the dose of TNF could be lowered to 10 μg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alexander, H. R., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T. & Rosenberg, S. A. (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 12: 1479–1489.
Asher, A. L., Mule, J. J., Reichert, C. M., Shiloni, E. & Rosenberg, S. A. (1987) Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963–974.
Benckhuijsen, C., Kroon, B. B. R., Van Geel, A. N. & Wieberdink, J. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157–163.
Borel Rinkes, I. H. M., de Vries, M. R., Jonker, A. M., Swaak, T. J. G., Hack, C. E., Nooijen, PTGA, Wiggers, T. & Eggermont, A. M. M. (1997) Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447–1453.
Broukaert, P., Libert, C., Everaerdt, B. & Fiers, W. (1992) Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 11: 193–196.
Clark, J., Grabs, A. J., Parson, P. G., Smithers, B. M., Addison, R. S. & Roberts, M. S. (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusions of melanoma. Melanoma Res 4: 365–370.
De Boeck, G., van Cauwenberghe, K., Eggermont, A. M. M., van Oosterom, A. T. & de Bruijn, E. A. (1997) Determination of melphalan and hydrolysis products in body fluids by GC-MS. J High Res Chromat 20: 697–700.
De Vries, M. R., Borel Rinkes, I. H. M., van de Velde, C. J. H., Wiggers, T., Tollenaar, RAEM, Kuppen, P. J. K. & Vahnmeijer, A. Eggermont (1998) Isolated hepatic perfusion with tumor necrosis factor-α (TNFα) and melphalan. Rec Results Cancer Res 147: 107–119.
Eggermont, A. M. M. (1996) Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 26: 335–349.
Eggermont, A. M. M., Schraffordt Koops, H., Liénard, D., Kroon, B. B. R., van Geel, A. N., Hoekstra, H. J. & Lejeune, F. J. (1996a) Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653–2665.
Eggermont, A. M. M., Schraffordt Koops, H., Klausner, J., Kroon, B. B. R., Schlag, P. M., Liénard, D., van Geel, A. N., Hoekstra, H. J., Meller, I., Nieweg, O. E., Kettelhack, C., Ben-Ari, G., Pector, J. C. & Lejeune, F. J. (1996b) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 224: 756–765.
Engelberts, I., Moller, A., Schoen, G. J., van der Linden, C. J. & Buurman, W. A. (1991) Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 10: 69–76.
Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D. & Allison, A. C. (1992) Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140: 539–544.
Fraker, D. L., Alexander, H. R. & Thom, A. K. (1994) Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 44: 45–50.
Fraker, D. L., Alexander, H. R., Andrich, M. & Rosenburg, S. A. (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14: 479–489.
Hill, S., Fawcett, W. J., Sheldon, J., Soni, N., Williams, T. & Thomas, J. M. (1993) Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80: 995–997.
Klaase, J. M., Kroon, B. B. R., Benckhuijsen, C., van Geel, A. N., Albus-Lutter, C. E. & Wieberdink, J. (1989) Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64: 616–621.
Klostergaard, J., Leroux, E., Siddik, Z. H., Khodadadian, M. & Tomasovic, S. P. (1992) Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 52: 5271–5277.
Kramer, S. M. & Carver, M. E. (1986) Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 93: 201–206.
Krementz, E. T., Carter, R. D., Sutherland, C. M. & Hutton, I. (1977) Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185: 555–564.
Kroon, B. B. R., Klaase, J. M., van Geel, A. N. & Eggermont, A. M. M. (1992) Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 4: 223–226.
Liénard, D., Ewalenko, P., Delmotte, J. J., Renard, N. & Lejeune, F. J. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52–60.
Manusama, E. R., Nooijen, PTGA, Stavast, J., Durante, N. M. C., Marquet, R. L. & Eggermont, A. M. M. (1996) Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551–555.
Niitsu, Y., Watanabe Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M. & Urushizaki, I. (1988) Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 48: 654–657.
Nooijen, PTGA, Manusama, E. R., Eggermont, A. M. M., Schalkwijk, L., Stavast, J., Marquet, R. L., de Waal, R. M. W. & Ruiter, D. J. (1996a) Synergistic anti-tumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 74: 1908–1915.
Nooijen, PTGA, Eggermont, A. M. M., Verbeek, M. M., Schalkwijk, L., Buurman, W. A., de Waal, R. M. W. & Ruiter, D. J. (1996b) Transient induction of E-selectin expression following TNFalpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol 19: 33–44.
Omlor, G., Gross, G., Ecker, K. W., Burger, I. & Feifel, G. (1992) Optimization of isolated hyperthermic limb perfusion. World J Surg 16: 1117–1119.
Posner, M., Liénard, D., Lejeune, F. J., Rosenfelder, D. & Kirkwood, J. (1994) Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastatic in-transit melanoma. Proc Annu Meet Am Soc Clin Oncol 13: A1351
Renard, N., Liénard, D., Lespagnard, L., Eggermont, A., Heimann, R. & Lejeune, F. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 57: 656–663.
Renard, N., Nooijen, PTGA, Schalkwijk, L., de Waal, R. M. W., Eggermont, A. M. M., Liénard, D., Kroon, B. B. R., Lejeune, F. J. & Ruiter, D. J. (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176: 279–287.
Robins, H. I., d’Oleire, F., Kutz, M., Bird, A., Schmitt-Tiggelaar, C. L., Cohen, J. D. & Spriggs, D. R. (1995) Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia. Cancer Lett 89: 55–62.
Scheringa, M., Keizer, A., Jeekel, J. & Marquet, R. L. (1989) Anti-tumor effect of recombinant TNF-alpha (rMuTNFα) given by continuous i.v. infusion as compared to repeated i.v. injections in a rat metastasis model. Int J Cancer 43: 905–909.
Scott, R. N., Kerr, D. J., Blackie, R., Hughes, J., Burnside, G., Mackie, R. M., Byrne, D. S. & McKay, A. J. (1992) The pharmacokinetic advantages of isolated limb perfusions with melphalan for malignant melanoma. Br J Cancer 66: 159–166.
Skarsgard, L. D., Skwarchuk, M. W., Vinczan, A., Kristl, J. & Chaplin, D. J. (1995) The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 15: 219–224.
Thompson, J. F. & Gianoutsos, M. P. (1992) Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16: 227–233.
Thompson, J. F., Waugh, R. C., Saw, R. P. M. & Kam, P. C. A. (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 7: 188–192.
Vaupel, P., Kallinowski, F. & Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic micro environment of human tumors: a review. Cancer Res 49: 6449–6465.
Vrouenraets, B. C., Kroon, B. B. R., Ogilvie, A. C., van Geel, A. N., Nieweg, O. E., Swaak, A. J. G. & Eggermont, A. M. M. (1997) Absence of severe systemic toxicity after leakage controlled isolated limb perfusion (ILP) with high-dose TNFα and melphalan. Melanoma Res 7: s111
Watanabe, N., Niitsu, Y., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M. & Urushizaki, I. (1988a) Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 48: 650–653.
Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N. & Maeda, M. Urushizaki (1988b) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48: 2179–2183.
Wu, Z. Y., Smithers, B. M., Parsons, P. G. & Roberts, M. S. (1997) The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 75: 1160–1166.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wilt, J., Manusama, E., Tiel, S. et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80, 161–166 (1999). https://doi.org/10.1038/sj.bjc.6690335
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690335
Keywords
This article is cited by
-
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
BMC Research Notes (2017)
-
Effects of hypoxia on human cancer cell line chemosensitivity
BMC Cancer (2013)
-
Projet de lutte contre le cancer du col utérin à Brazzaville: acquis et perspectives
Journal Africain du Cancer / African Journal of Cancer (2011)